Blog
RSS FeedPosted by Michael Wonder on 21 Dec 2023
RemeGen announces continued inclusion of telitacicept and disitamab vedotin in China National Reimbursement Drug List, ensuring continuous accessibility of innovative drugs for more patients
18 December 2023 - RemeGen has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security ...
Posted by Michael Wonder on 18 Dec 2023
Zai Lab announces the first listing of Vyvgart (efgartigimod alfa) and other updates in China’s National Reimbursement Drug List
12 December 2023 - Zai Lab today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare ...
Posted by Michael Wonder on 14 Dec 2023
Antengene announces inclusion of Xpovio (selinexor) in 2023 China's National Reimbursement Drug List
13 December 2023 - Antengene today announced that Xpovio (selinexor) has been added to the National Reimbursement Drug List (2023 Version) ...
Posted by Michael Wonder on 13 Dec 2023
Hutchmed announces continued inclusion of Elunate (fruquintinib) and Sulanda (surufatinib) in the National Reimbursement Drug List in China at current terms
12 December 2023 - Hutchmed today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, ...
Posted by Michael Wonder on 09 Nov 2023
UnitedHealth unit to add eight insulin products to its reimbursement list
9 November 2023 - UnitedHealth's pharmacy benefit manager unit said on Thursday it was adding eight insulin products to its ...
Posted by Michael Wonder on 30 Oct 2023
Switzerland restricts reimbursement of orphan drugs
30 October 2023 - New rules for the reimbursement of orphan drugs and other unlisted medicines will become effective in Switzerland ...
Posted by Michael Wonder on 05 Aug 2023
Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
3 August 2023 - Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors ...
Posted by Michael Wonder on 17 Jul 2023
Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy
17 July 2023 - While donanemab appears to be among the first therapies to demonstrate measurable clinical benefit for Alzheimer's disease, ...
Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...
Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...
Posted by Michael Wonder on 28 Mar 2023
'To develop digital health, separate insurance coverage system needed’
28 March 2023 - The Government needs to establish a separate reimbursement registration frame for digital treatment devices that secure ...
Posted by Michael Wonder on 14 Mar 2023
Veterans Affairs to be first major insurer to cover Alzheimer’s drug Leqembi
13 March 2023 - Roughly 168,000 veterans receiving care have Alzheimer’s dementia. ...
Posted by Michael Wonder on 09 Mar 2023
Mallinckrodt announces reimbursement approval in Japan for the Celllex extracorporeal photopheresis system for the treatment of chronic graft versus host disease
9 March 2023 - Cellex ECP is now available for reimbursement in Japan for patients who are steroid-resistant or intolerant ...
Posted by Michael Wonder on 09 Mar 2023
Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails
9 March 2023 - A decade ago, I had pegged gene and cell therapies as the next frontier. As an ...
Posted by Michael Wonder on 26 Feb 2023
Minister for Health publishes review of governance arrangements to support HSE drug reimbursement process
24 February 2023 - The Minister for Health today published a Report prepared by Mazars which examines the governance arrangements ...